In vitro effect of a holding chamber on the mouth-throat deposition of QVAR® (Hydrofluoroalkane-beclomethasone dipropionate)

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 15, Issue 4, 2002, Pages 379-385

  Rahmatalla, Muhib F ^a   Zuberbuhler, Peter C ^a   Lange, Carlos F ^a   Finlay, Warren H ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Aerosol; Extrathoracic; MDI; Metered dose inhaler; Spacer

Indexed keywords

BECLOMETASONE DIPROPIONATE; FLUORINATED HYDROCARBON;

AEROSOL; ARTICLE; DEVICE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; FLOW RATE; METERED DOSE INHALER; OROPHARYNX; TURBULENT FLOW; VALVED HOLDING CHAMBER;

AEROSOLS; ANALYSIS OF VARIANCE; ANTI-ASTHMATIC AGENTS; BECLOMETHASONE; EQUIPMENT DESIGN; MOUTH; NEBULIZERS AND VAPORIZERS; PHARYNX;

EID: 0036961772     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/08942680260473452     Document Type: Article

References (22)

1. Chew, N.Y.K., and H. Chan. 2000. The effect of spacers on the delivery of metered dose aerosols of nedocromil sodium cromoglycate. Int. J. Pharm. 200: 87-92.
2. Finlay, W.H., and P. Zuberbuhler. 1998. In vitro comparison of beclomethasone and salbutamol MDI aerosols inhaled during tidal breathing from four valved holding chambers. Chest 114:1676-1680.
3. Berg, E., J. Madsen, and H. Bisgaard. 1998. In vitro performance of three combinations of spacers and pressurized metered dose inhalers for treatment in children. Eur. Respir. J. 12:472-476.
4. Barry, P.W., and C. O'Callaghan. 1997. In vitro comparison of the amount of salbutamol available for inhalation from different formulations used with different spacer devices. Eur. Respir. J. 10:1345-1348.
5. Kim, C.S., M.A. Eldridge, and M.A. Sackner. 1987. Oropharyngeal deposition and delivery aspects of metered-dose inhaler aerosols. Am. Rev. Respir. Dis. 135:157-164.
6. O'Callaghan, C., M. Cant, and C. Robertson. 1994. Delivery of beclomethasone dipropionate from a spacer device: what dose is available for inhalation. Thorax 49:961-964.
7. Dompeling, E., A.M. Murphy, H.M. Janssens, et al. 2001. Randomised controlled study of clinical efficacy of spacer therapy in asthma with regard to electrostatic charge. Arch. Dis. Child. 84:178-182.
8. Wildhaber, J.H., G.W. Waterer, G.L. Hal, et al. 2000. Reducing electrostatic charge on spacer devices and bronchodilator response. Br. J. Pharmacol. 50:277-280.
9. Janssens, H.M., S.G. Devadason, W.C.J. Hop, et al. 1999. Variability of aerosol delivery via spacer devices in young asthmatic children in daily life. Eur. Respir. J. 13:787-791.
10. Leach, C.L. 1999. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J. Allergy Clin. Immunol. 104:S250-S252.
11. Hindle, M., and H. Chrystyn. 1994. Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices. Thorax 49:549-553.
12. Leach, C.L., P.J. Davidson, T.S. Bredow, et al. 1998. Patient factors influencing the deposition of HFA-beclomethasone dipropionate metered dose inhaler. Eur. Respir. J. 12:66s.
13. Stapleton, K.W., E. Guentsch, M.K. Hoskinson, et al. 1999. On the suitability of K-ε turbulence modeling for aerosol deposition in the mouth and throat: a comparison with experiment. J. Aerosol Sci. 30:105-109.
14. Dehaan, W.H., and W.H. Finlay. 2001. In vitro monodisperse aerosol deposition in a mouth and throat with six different inhalation devices. J. Aerosol Med. 14:361-367.
15. Tukey, J.W., L.T. Fernholz, D.R. Brillinger, et al. 1997. The Practice of Data Analysis. Princeton University Press, Princeton, NJ.
16. Leach, C.L. 1998. Targeting inhaled steroids. Int. J. Clin. Pract. Suppl. 96:23-27.
17. Shaw, R.J. 1999. Inhaled corticosteroids for adult asthma: impact of formulation and delivery device on relative pharmacokinetics, efficacy and safety. Respir. Med. 93:149-160.
18. Stein, S.W., and B.J. Gabrio. 2000. Understanding throat deposition during cascade impactor testing. Respir. Drug Delivery VII:287-290.
19. Leach, C.L., P.J. Davidson, and R.J. Boudreau. 1998. HFA-134a beclomethasone dipropionate(HFA-BDP): extra fine aerosol MDI delivers 57% lung deposition across inspiratory flow ranges of 43-163 LPM." J. Allergy Clin. Immunol. 101:S63.
20. Liu, B.Y.H., and J.K. Agarwal. 1974. Experimental observation of aerosol deposition in turbulent flow. Aerosol Sci. 5:145-155.
21. Sehmel, G.A. 1968. Aerosol Deposition from Turbulent Air Streams in Vertical Conduits. Batelle North-west Laboratory, Richland, WA, Report BNWL-578.
22. Ahrens, R., C. Lux, T. Bahl, et al. 1995. Choosing the metered-dose inhaler spacer or holding chamber that matches the patient's need: evidence that the specific drug being delivered is an important consideration. J. Allergy Clin. Immunol. 96:288-294.